919286-65-0

Basic information

• Product Name: (R )-6-Hydroxymethyl-morpholin-3-one
• Synonyms: (R )-6-Hydroxymethyl-morpholin-3-one;(R)-6-(Hydroxymethyl)Morpholin-3-One(WXC00056)
• CAS NO: 919286-65-0
• Molecular Formula: C₅H₉NO₃
• Molecular Weight: 131.12986
• Product Categories: pharmacetical
• Mol File: 919286-65-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R )-6-Hydroxymethyl-morpholin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R )-6-Hydroxymethyl-morpholin-3-one(919286-65-0)
• EPA Substance Registry System: (R )-6-Hydroxymethyl-morpholin-3-one(919286-65-0)

Safety Data

• Hazardous Substances Data: 919286-65-0(Hazardous Substances Data)

Usage

General Description

(R )-6-Hydroxymethyl-morpholin-3-one, also known as R Warfarin alcohol, is a chemical compound that is used as an intermediate in the synthesis of pharmaceuticals. It is a derivative of morpholine, a heterocyclic organic compound. This chemical has been studied for its potential application in the treatment of various medical conditions, including blood clot prevention and anticoagulant therapy. It is an important building block in the production of medications that are used to prevent the formation of blood clots, and it also has potential applications in the development of new drugs for various other health conditions. Overall, (R )-6-Hydroxymethyl-morpholin-3-one is a versatile and important chemical compound with potential pharmaceutical applications.

Upstream product

• 919286-64-9 (R)-2-chloro-N-(2,3-dihydroxypropyl)acetamide 

Downstream Products

• 156925-22-3 (2R)-2-hydroxymethylmorpholine 
• 135065-64-4 tert-butyl (2R)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction

The protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1) plays an important role in development of acute leukemia with translocations of the MLL1 gene and in solid tumors. Here, we report the development of a new generation of menin-MLL1 inhibitors identified by structure-based optimization of the thienopyrimidine class of compounds. This work resulted in compound 28 (MI-1481), which showed very potent inhibition of the menin-MLL1 interaction (IC50 = 3.6 nM), representing the most potent reversible menin-MLL1 inhibitor reported to date. The crystal structure of the menin-28 complex revealed a hydrogen bond with Glu366 and hydrophobic interactions, which contributed to strong inhibitory activity of 28. Compound 28 also demonstrates pronounced activity in MLL leukemia cells and in vivo in MLL leukemia models. Thus, 28 is a valuable menin-MLL1 inhibitor that can be used for potential therapeutic applications and in further studies regarding the role of menin in cancer.

CYSTEINE PROTEASE INHIBITORS

Stereoisomers of the formula (III) wherein R is H or C1-C3 optionally halo-substituted alkyl; or pharmaceutically acceptable salts, hydrates or N-oxides thereof have utility in the treatment of disorders mediated by inappropriate exp